Pure Global AI
NCT06323174Recruiting

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and Exercise
Novo Nordisk A/SPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Type 2 Diabetes
Drug/Device/Intervention
Cagrilintide
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Novo Nordisk A/S
Location
Huntington Park,Northridge,Santa Ana,Hollywood,Newton,Boston,Troy,Kingsport,Dallas,San Antonio,Shavano Park,Shavano Park,Newport News,Beijing,Nanjing,Zhenjiang,Ji'Nan,Debrecen,Nyíregyháza,Bergamo,Cata, China,Hungary,Italy,Poland,Saudi Arabia,Serbia,United States of America
Timeline & enrollment
Phase
Phase 3
Start date
Mar 19, 2024
End date
Nov 04, 2025
Enrollment
180 participants
Primary outcome

Change in glycated haemoglobin (HbA1c)

Summary

This study will look at how much CagriSema helps participants with type 2 diabetes lower
 their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may
 not yet prescribe CagriSema. CagriSema will be compared to a dummy medicine (also called
 placebo) that has no effect on the body. Participants will get either CagriSema or dummy
 medicine. Which treatment participants get is decided by chance. For each participant, the
 study will last for about one year.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06323174
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06323174 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Recruiting. The study focuses on Type 2 Diabetes. Target enrollment is 180 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.